Richter signs distribution deal with ProStrakan
Hungarian drug manufacturer Richter Gedeon Rt concluded a distribution agreement with ProStrakan Group (PSK), a Scotland-based specialty pharmaceutical company, to distribute Rapinyl in seven CEE countries (Estonia, Latvia, Lithuania, Poland, Czech Republic, Slovakia and Hungary), Richter announced on Tuesday.
ProStrakan originally licensed the European rights to Rapinyl from Orexo AB in December 2005. ProStrakan expects to submit Rapinyl for marketing approval in Europe in 2006. Under the terms of the agreement, ProStrakan will receive advance payment plus approval and sales milestones, the press release said.
ProStrakan will retain responsibility for obtaining marketing approval for Rapinyl in each of the licensed territories and will supply Rapinyl at an agreed transfer price, while Richter will be responsible for obtaining pricing and reimbursement approvals. The two companies will collaborate on a marketing and launch plan for Rapinyl in these territories.
Rapinyl is a new, rapidly disintegrating, muco-adhesive sublingual tablet formulation of the opioid drug fentanyl, expected to be indicated for the management of breakthrough cancer pain.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.